Display options
Cite
Aghdam RA, Amoui M, Ghodsirad M, et al. Efficacy and safety of . World J Nucl Med. 2019;18(3):258-265doi: 10.4103/wjnm.WJNM_66_18.
Aghdam, R. A., Amoui, M., Ghodsirad, M., Khoshbakht, S., Mofid, B., Kaghazchi, F., Tavakoli, M., Pirayesh, E., & Ahmadzadehfar, H. (2019). Efficacy and safety of . World journal of nuclear medicine, 18(3), 258-265. https://doi.org/10.4103/wjnm.WJNM_66_18
Aghdam, Ramin Akbarian, et al. "Efficacy and safety of ." World journal of nuclear medicine vol. 18,3 (2019): 258-265. doi: https://doi.org/10.4103/wjnm.WJNM_66_18
Aghdam RA, Amoui M, Ghodsirad M, Khoshbakht S, Mofid B, Kaghazchi F, Tavakoli M, Pirayesh E, Ahmadzadehfar H. Efficacy and safety of . World J Nucl Med. 2019 Jul-Sep;18(3):258-265. doi: 10.4103/wjnm.WJNM_66_18. PMID: 31516369; PMCID: PMC6714159.
Copy Download .nbib Format: NLM
Share it on

World J Nucl Med. 2019 Jul-Sep;18(3):258-265. doi: 10.4103/wjnm.WJNM_66_18.

Efficacy and safety of .

World journal of nuclear medicine

Ramin Akbarian Aghdam, Mahasti Amoui, Mohammadali Ghodsirad, Sepide Khoshbakht, Bahram Mofid, Fateme Kaghazchi, Mehrdad Tavakoli, Elahe Pirayesh, Hojjat Ahmadzadehfar

Affiliations

  1. Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  2. Department of Nuclear Medicine, Shohada'e Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  3. Department of Radiation Oncology, Shohada'e Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  4. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.

PMID: 31516369 PMCID: PMC6714159 DOI: 10.4103/wjnm.WJNM_66_18

Abstract

Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is highly expressed on the surface of prostate cancer (PC) cells, making it an excellent radiotracer for both therapeutic and diagnostic purposes. In this prospective study, we investigated the efficacy and toxicity of

Keywords: 177Lutetium; metastatic castration-resistant prostate cancer; prostate cancer; prostate-specific membrane antigen; radionuclide therapy; theranostic

Conflict of interest statement

There are no conflicts of interest.

References

  1. N Engl J Med. 2004 Oct 7;351(15):1513-20 - PubMed
  2. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 - PubMed
  3. Lancet. 2010 Oct 2;376(9747):1147-54 - PubMed
  4. Urol Oncol. 1995 Jan-Feb;1(1):18-28 - PubMed
  5. N Engl J Med. 2012 Sep 27;367(13):1187-97 - PubMed
  6. N Engl J Med. 2013 Oct 24;369(17):1659-60 - PubMed
  7. Eur J Nucl Med Mol Imaging. 2015 May;42(6):987-8 - PubMed
  8. Lancet Oncol. 2015 Feb;16(2):152-60 - PubMed
  9. J Nucl Med. 2015 Feb;56(2):293-8 - PubMed
  10. J Biol Regul Homeost Agents. 2014 Oct-Dec;28(4):555-63 - PubMed
  11. Can Urol Assoc J. 2015 Mar-Apr;9(3-4):90-6 - PubMed
  12. EJNMMI Res. 2015 Dec;5(1):114 - PubMed
  13. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1976-83 - PubMed
  14. Oncotarget. 2016 Mar 15;7(11):12477-88 - PubMed
  15. Asian Pac J Cancer Prev. 2016;17(2):839-43 - PubMed
  16. J Nucl Med. 2016 Sep;57(9):1334-8 - PubMed
  17. Eur Urol. 2017 Apr;71(4):630-642 - PubMed
  18. J Nucl Med. 2016 Oct;57(Suppl 3):97S-104S - PubMed
  19. J Nucl Med. 2017 Jan;58(1):85-90 - PubMed
  20. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1473-1479 - PubMed
  21. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1448-1454 - PubMed
  22. Oncotarget. 2017 Feb 25;8(33):55567-55574 - PubMed
  23. Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):12-19 - PubMed
  24. Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):243-246 - PubMed
  25. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):513-514 - PubMed
  26. Oncotarget. 2017 Oct 7;8(61):103108-103116 - PubMed
  27. CA Cancer J Clin. 2018 Jan;68(1):7-30 - PubMed
  28. Lancet Oncol. 2018 Jun;19(6):825-833 - PubMed
  29. Mol Imaging. 2018 Jan-Dec;17:1536012118776068 - PubMed
  30. Urology. 1998 Oct;52(4):637-40 - PubMed

Publication Types